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Summary The efficacy of currently available treatments for Hodgkin's disease (HD) has led to a substantial
modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured
with conventional treatments and who will be candidates for alternative therapy. In the present work we
analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive
series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables
with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS);
LDH >320 U ml-', age >45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase
>19OUIdl and ESR >40mmh. In addition, Hb<12.5grdl-' and abdominal disease were statistically
relevant for CR while a poor performance score (ECOG ) 2) affected a lower survival. In the multivariate
analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR,
while the two first factors above, together with performance status were the variables with independent
prognostic value with respect to OS. Moreover, only LDH >320Uml-' had prognostic influence in the
probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses.
According to the three independent factors obtained in the multivariate analysis for CR (LDH, age and
stage) a predictive model was established that allows the stratification of patients into two prognostic groups:
one with poor prognosis that includes patients with the three adverse prognostic factors, or two if one of them
was elevated LDH, and the other with good prognosis that includes the remaining patients. This model was
also able to separate two independent groups of patients with respect to OS and to DFS. In conclusion, the
present study shows that LDH is one of the most important prognostic factors in HD.
The prognostic outlook for Hodgkin's disease (HD) has
markedly improved in recent decades and today 70 to 80
percent of these patients can be cured with chemotherapy
and/or radiotherapy (Bonadonna et al., 1988; Canellos, 1992;
Urba & Long, 1992). This progressive improvement has been
based on adequate prospective therapeutic trials combined
with careful clinicopathologic and prognostic factor analysis
(Bennett et al., 1983; Desch et al., 1992; Hoppe et al., 1982;
Loefler et al., 1988; Specht et al., 1988; Strauss et al., 1990;
Tubiana et al., 1989; Wedelin et al., 1984). However, there is
still a group of patients refractory to initial treatment that
will be candidates for alternative therapeutic approaches
(Gribben et al., 1989; Jagannath et al., 1986; Yahalom et al.,
1989). The definition of new prognostic factors that allows
the identification of such patients at the actual time of diag-
nosis will be of great value.
The serum levels of lactic acid dehydrogenase (LDH),
which are very important in the prognosis of non-Hodgkin's
lymphoma (NHL) (Danieu et al., 19881 Schneider et al.,
1980), have not received much attention in HD although
recently Strauss et al. (1990) have stressed its value as an
independent factor with even greater significance than other
classical parameters, such as age. In addition, this parameter
fulfills the requisites of a good prognostic factor in the sense
that LDH levels are objective and readily accessible.
In the present work we analysed the prognostic influence
of the different clinico-biological characteristics of HD in a
consecutive series of 137 patients diagnosed and treated in a
single institution, showing that the serum level of LDH is
one of the variables with the greatest impact in the outcome
of the disease.
Materials and methods
Patients and treatment
Between January 1980 and June 1992, 137 consecutive
patients that had not received any previous chemical or
radiological treatment were diagnosed as suffering from HD
in a single institution (Hematology Department of the
University Hospital of Salamanca).
Clinical staging was performed according to the indications
of the Ann Arbor conference (Carbone et al., 1971) and the
Cotswolds review (Lister et al., 1989). All the early stages (I
and IIA) were confirmed by Kaplan laparotomy. Abdominal
involvement was defined as the presence of disease in any
part of the abdomen detected by: (a) physical examination
(unequivocally palpable spleen or equivocally palpable spleen
plus radiologic enlargement or esplenic defects); (b)
radiological methods (lymph nodes or masses > 1.5 cm or
nodes in the liver or spleen, if found in the liver they should
be confirmed by two different methods) or (c) histologic
demonstration by percutaneous biopsy or laparotomy. Any
involvement of extralymphatic tissue was considered as ex-
tranodal disease (both stages E and IV). Histological
classification was made according to the Rye modification of
the Lukes and Butler scheme (Lukes et al., 1966).
Patients in the early stages of the disease (I and IIA
without Bulky disease, n = 17) were treated exclusively with
Mantle and inverted-Y radiotherapy. The remaining patients
(stages IIB, III and IV, as well as all patients with Bulky
disease, n = 120) received polychemotherapy - MOPP (n = 53),
ABVD (n =8) or hybrid MOPP/ABV (n = 59) -; Twenty-two
of these cases received additional local irradiation.
All patients were evaluated one month after the end of
treatment, considering the following response criteria: Com-
plete Remission (CR) was defined as the disappearance of all
abnormalities (clinical, physical, biochemical and radio-
logical) attributable to HD; Partial Remission (PR) as a
decrease of at least 50% of the greatest diameter of all
measurable masses, with no new lesions appearing and no
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progression at the original sites of the disease. Relapse was
defined as the reappearance of HD in patients achieving CR
for more than 6 months.
Nine patients had early deaths without evidence of tumour
progression and were excluded from response evaluation. All
of them had advanced stages of the disease, were older than
60 and had low performance statuses.
Prognosticfactors and statistical methods
The following clinical-biological features, determined at the
time of diagosis, were analysed: age, sex, performance status
(according to the ECOG scale), B symptoms, histology, sites
of involvement, presence of bulky disease, peripheral blood
values (hemoglobin, WBC count and platelet count), and
serum levels of LDH, alkaline phosphatase (AP), SGOT
(AST), SGPT (ALT), copper and ceruloplasmin. These char-
acteristics were considered individually for their relationship
with the probability of achieving CR and the rate of relapse
for patients in CR by univariate tests (T-test, chi-square,
correlations and non-parametrics tests, SPSS). Subsequently,
a multivariate analysis - stepwise regression - (regression,
SPSS) (Cox, 1972) was performed to examine the simul-
taneous effect of the different variables on the probability of
achieving CR and the rate of relapse.
The same characteristics mentioned above were newly con-
sidered for analysis with respect to their individual and
simultaneous effects on overall survival (OS) and disease
freed survival (DFS) - univariate and multivariate analysis,
BMDP IL and 2L, respectively. OS and DFS curves were
plotted according to the method of Kaplan and Meier, and
compared statistically using the Mantel-Cox, Peto-Prentice
and Breslow tests. The cut-off point of each variable was
selected by starting at its median value and then cutting at
different levels above and below, until significance was even-
tually obtained. Variables considered for possible inclusion in
the regression analysis were those for which there was some
indication of a significant association in univariate analysis
(P<0.1) or for which prior studies had suggested a possible
association. The stepwise regression procedure was stopped
when the P value for entering an additional factor was above
0.05. The model was tested both by expressing values in a
continuous way (continuous variables) and by grouping them
into categories (dichotomous variables).
Results
The median age of this series of patients was 38 years (range
4-78) with a slight predominance of males (55%). In most
patients (81%) HD was in the advanced stages. The histo-
logic pattern included: 50% with nodular sclerosis, 32% with
mixed cellularlity, 9% with lymphocyte predominance and
9% with lymphocyte depletion.
The overall rate of CR was 79%, with an incidence of
relapse of 30%. At 7 years, OS was 81% and disease-free
survival at 6 years, 61% (patients with a minimum follow-up
of 36 months). there were no statistically significant
differences among the different chemotherapeutic regimens
employed.
Prognosticfactorsfor achieving complete remission (CR)
The results of the analysis of prognostic factors with respect
to the probability of achieving CR are shown in Table I. In
the univariate analysis, eight variables were significantly
associated with a low probability of achieving CR: elevated
LDH levels (P<0.0001), advanced age (P = 0.008), advanced
stage (P = 0.001), abdominal disease (P = 0.003), extranodal
involvement (P = 0.01), elevated alkaline phosphatase (AP)
(P = 0.01), ESR higher than 40 mm h-' (P = 0.01), low level
of hemoglobin (P = 0.02) and the presence of B symptoms
(P = 0.03). In the multivariate analysis, only three factors
retained a significant prognostic value: elevated LDH
(P = 0.0001); age above 45 (P = 0.002), and the existence of
an advanced stage of the disease (P = 0.03).
Table II shows the associations between the prognostic
factors selected in the multivariate analysis and other
relevant disease characteristics. LDH was associated with the
existence of extranodal involvement, advanced stage, a bulky
mediastinal involvement, and abdominal disease but not with
the histologic pattern of HD. In turn, age was related to
extranodal involvement, advanced stage, low hemoglobin
levels, histology of mixed cellularity and presence of B symp-
toms.
According to the three independent factors obtained in the
multivariate analysis (LDH, age and stage), a predictive
model was established for stratifying the patients into two
prognostic groups: one with poor prognosis that included
patients with the three adverse prognostic factors, or two if
one of them was elevated LDH (above the maximum limit of
320 U ml-'); the rest of the patients would be included in
another group, which would afford them a good prognosis.
The rates of CR were 16% and 90%, respectively.
Prognosticfactorsfor overall survival (OS)
The variables associated with a significantly lower survival in
the univariate analysis were: age >45 years (P = 0.004), per-
formance status -ECOG>i2- (P = 0.002), LDH > 320 U mli'
(P = 0.0005), ESR >40 mm h-' (P = 0.04), extranodal
involvement (P = 0.04), AP level> 190 UI dl (0.05) and
advanced stage (P = 0.05) (Table III). The multivariate study
showed that only three of them had independent prognostic
value: advanced age (P = 0.003), elevated LDH levels
(P = 0.02) and ECOG equal to or greater than 2 (P = 0.01).
On eliminating the patients that died before the end of
treatment (early deaths), the multivariate analyses showed
that performance status (P = 0.13), advanced age (P = 0.29)
and an ESR above 40 mm h-' (P = 0.18) lost their indepen-
dent prognostic with respect to OS and the disease charac-
teristics with significant influence were reduced to two: age
Table I Prognostic values selected with respect to the probability of achieving CR
Proportion of Univariable Score test
patients with the score test P value to enter,
Characteristic characteristic P value given the final model
LDH>320 Uml-' 23% <0.OOOOOa 0.OOOla
Age>45 years 40% 0.009a 0.002a
Stage IIB, III & IV 75% 0.OO1a 0.03a
Abdominal involvement 39% 0.003a 0.16
Extranodal involvement 36% O.Ola 0.21
AP> 190 UIdl-' 41% 0.02a 0.75
ESR>40mm in the first hour 54% 0.01 0.98
Hemoglobin < 12.5 gdl-' 46% 0.02 0.50
B symptoms 53% 0.03a 0.51
Ceruloplasmin>54mg dl' 50% 0.20 0.51
Mass> 10cm 19% 0.21 0.29
Blood copper level> 130jgdl' 50% 0.93 0.99
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Table II Associations between the prognostic predictors or CR and survival
selected in the multivariate analysis with other disease characteristics
Characteristic Associations with P value
High serum LDH Advanced stage 0.008
Mediastinal disease 0.019
Abdominal disease 0.023
Mediastinal bulky disease 0.031
High SGOT 0.023
Extranodal involvement 0.046
Advanced age Low hemoglobin <0.001
Accelerated ESR <0.001
High ECOG 0.003
Advanced stage 0.005
Extranodal involvement 0.006
B symptoms 0.012
High AP 0.019
High SGOT 0.025
Mixed cellularity histology 0.048
Advanced stage Accelerated ESR <0.000
High ECOG <0.000
High AP 0.004
Low hemoglobin 0.004
Advanced age 0.006
High ceruloplasmin 0.007
High LDH 0.008
High SGOT 0.010
High SGPT 0.032
Performance status (high ECOG) Advanced stage <0.000
Extranodal involvement <0.000
Low hemoglobin 0.001
Accelerated ESR 0.002
Advanced age 0.003
High AP 0.007
High ceruloplasmin 0.008
High SGOT 0.010
Table III Prognostic values selected with respect to overall survival
Proportion of Univariable Score test
patients with the score test P value to enter,
Characteristic characteristic P value given the final model
Age>45 years 40% 0.004a 0.003a
Performance status (ECOG >2) 43% 0.002a 0.Ola
LDH> 320 Uml-' 23% 0.0005a 0.02a
Stage IIB y III y IV 75% 0.05a
Extranodal involvement 36% 0.04a
ESR>40mm in the first hour 54% 0.04a
Alkaline phosphatase> 190 UI dl-' 41% 0.05a
B symptoms 53% 0.1
Abdominal involvement 39% 0.2
Hemoglobin < 12.5 gdl-' 46% 0.3
Blood copper level> 130itgdl' 50% 0.4
Ceruloplasmin>54 mgdl-' 50% 0.5
Bulky disease 19% 0.89
aStatistically significant.
above 45 years (P = 0.0005) and an LDH level above
320 U ml-' (P = 0.007). Figure 1 shows the survival curves
for age and LDH levels.
Prognosticfactorsfor relapse and diseasefree survival (DFS)
Within the group of patients that achieved CR, there was
only one variable that maintained prognostic significance for
the prediction of relapse; this was the serum level of LDH,
both in univariate (P = 0.009) and in multivariate (P = 0.002)
analyses, the best cut-off being the maximum normal value,
which was 320 U ml-'. Neither age nor the clinical stage of
the disease were of help in the prediction of relapses.
Regarding DFS, the LDH level was also the only
parameter that at the time of diagnosis had statistically
significant influence on DFS (P = 0.01). Figure 2 shows the
DFS curves with respect to the serum LDH levels.
Interestingly, the stratification model of two prognostic
groups established for CR was also able to separate them
with respect to overall survival and disease-free survival
(Figure 3).
Discussion
The efficacy of currently available treatments against HD
have led to a substantial modification in the prognosis of this
disease; nevertheless there is still one group of patients that
cannot be cured with conventional treatments. In the present
work we developed a prognostic model as regards the pro-
bability of achieving CR and predicting survival (OS and
DFS).
In our series, ten clinical variables had prognostic influence
(with respect to achieving CR or relapsing and with respect1230 R. GARCIA et al.
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our series, it proved to be the parameter with the greatest
independent strength with respect to achieving CR. As
regards survival, LDH was selected after age and perfor-
mance status. Nevertheless, on discounting early deaths, the
statistical influence of LDH increased while performance
status lost its prognostic value. Additionally, LDH was the
only variable that had independent predictive value as
regards relapse and DFS. This, together with the simplicity in
determining its levels and its objective nature, increases its
usefulness in clinical practice. Interestingly our study shows
that LDH levels were associated with most of the disease
characteristics that reflect high tumour burden.
Finally, in the present study we propose a prognostic
model in which LDH is of great value for the identification
of a particular group of patients with a high probability of
treatment failure and who are therefore candidates for new
therapeutic strategies at the actual time of diagnosis, such as
high doses in chemotherapy followed either by autologous
bone marrow transplantation or growth-factor administra-
tion.
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